This is a working overview of dual agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-04. Anything still debated is marked as such rather than presented as settled.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
Prostaglandins (PG) are a group of physiologically active lipid compounds that have diverse hormone-like effects in animals. They are a subclass of eicosanoids and of the prostanoid class of fatty acid derivatives. Prostaglandins have been found in almost every tissue in humans and other animals. They are derived enzymatically from the fatty acid arachidonic acid. Every prostaglandin contains 20 carbon atoms, including a 5-carbon ring. The structural differences between prostaglandins account for their different biological activities. A given prostaglandin may have different and even opposite effects in different tissues in some cases. The ability of the same prostaglandin to stimulate a reaction in one tissue and inhibit the same reaction in another tissue is determined by the type of receptor to which the prostaglandin binds. They act as autocrine or paracrine factors with their target cells present in the immediate vicinity of the site of their secretion. Prostaglandins differ from endocrine hormones in that they are not produced at a specific site but in many places throughout the human body. Prostaglandins are powerful, locally-acting vasodilators and inhibit the aggregation of blood platelets. Through their role in vasodilation, prostaglandins are also involved in inflammation. They are synthesized in the walls of blood vessels and serve the physiological function of preventing needless clot formation, as well as regulating the contraction of smooth muscle tissue.
It is impossible to suppress the demand for drugs." He quoted Helen Clark, former prime minister of New Zealand and head of the Global Commission on Drug Policy: "The total elimination of drugs? Dream on, there's never been a time in human history where human beings haven't resorted to some kind of substances that will take them out of their current reality for whatever reason."
=== Health economics and cost effects === Compared to insulin therapy in patients with type 2 diabetes requiring treatment, GLP-1 RAs may be more cost-effective. In a recent observation of a cohort study using Taiwan's National Health Isurance Research Database, GLP-1 RA therapy was associated with improved clinical outcomes. This includes reductions in mortality and hospitalized hypoglycemia relative to insulin. From an economic perspective, GLP-1 RAs were associated with higher direct drug costs but demonstrated value when evaluated against clinical outcomes. The cost per case prevented was approximately $54,851 for all-cause mortality and $29,115 for hospitalized hypoglycemia from the perspective of a third-party payer. But GLP-1 RA use was associated with net cost savings and reflected a downward movement of healthcare use. Studies found that GLP-1 RAs are cost-effective for only some patients. These population groups are limited to long-term cardiovascular and metabolic benefits. Overall, evidence suggests that though these receptor agonists have higher upfront costs, their ability to reduce adverse clinical events may make them a more cost-effective therapy option.
As shown by Lütge, Pikor, and Ludewig (2021), reticular cells in secondary lymphoid organs are not a single homogeneous group of cells, but instead consist of many subtypes of cells defined by their position in the body and expression of cell markers such as podoplanin and ER-TR7.
As of 2024, the legal status of ibogaine varies widely among countries, as it may be illegal to possess or use, may be legalized, may be decriminalized, or is under consideration for future legislation. In the United States, although some cities and states have decriminalized psychedelic chemicals, plants and mushrooms, ibogaine has had minimal legislation, and remains illegal under federal law, as of 2026. The US Drug Enforcement Administration enforces ibogaine as a Schedule I substance under the Controlled Substances Act. A 2026 executive order in the US accelerates ibogaine research, regulatory review, patient access through Right to Try, and potential rescheduling if clinical trials and FDA approval criteria are successful. In March 2026, Texas announced plans to use $50 million approved by the Texas Legislature the previous year to create its own ibogaine research program after several proposals from drug companies failed to meet requirements for partnering with the state.
Sources: en.wikipedia.org
As of the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After, he has joined S.P.D.'s Earth unit and married Jasmine, with whom they have a son named Taiga. Hikaru Hiwatari is portrayed by Yuto Uemura (上村 祐翔, Uemura Yūto). Zamuzan Myra (ザムザ星人マイラ, Zamuza Seijin Maira): A young woman from Planet Zamuza who was the subject of a stakeout conducted by the Dekarangers due to her ex-boyfriend, an Alienizer named Sheik, having recently escaped from prison. However, Ban becomes enamored by her and goes undercover as her apartment building's plumber to socialize with her. After Sheik attacks Myra and the Dekarangers delete him, Myra loses respect for Ban for lying to her, but chooses to remain friends with him since he kept his promise to protect her. Myra is portrayed by Nana Nakamoto (中本 奈奈, Nakamoto Nana). Ocarnan Amy (オカーナ星人エイミー, Okāna Seijin Eimī): A giant alien baby from planet Ocarna who possesses currently uncontrollable size-changing capabilities limited by a special pacifier and shockwave-inducing cries. After Amy's cradle pod lands on Earth, Umeko is assigned to protect her until the former's parents can come for her. Agent Abrella sends an Igaroid to pilot a Kaijuki called Devil Capture 3 (デビルキャプチャー3, Debiru Kyapuchā Surī) and capture Amy, but Umeko destroys them with Dekaranger Robo before Amy's parents arrive and take their daughter back. Amy is voiced by Sara Nakayama (中山 さら, Nakayama Sara).
Users can choose whether any other user, or only their "friends", may interact with them through the app via comments, messages, or "react" or "duet" videos. The "duet" feature was another trademark of Musical.ly. The duet feature is also only able to be used if both parties adjust the privacy settings. Users can also set specific videos to either "public", "friends only", or "private" regardless if the account is private or not. The app allows users to create short videos, which often feature music in the background and can be sped up, slowed down, or edited with a filter. They can also add their own sound on top of the background music. To create a music video with the app, users can choose background music from a wide variety of music genres, edit with a filter and record a 15-second video with speed adjustments before uploading it to share with others on TikTok or other social platforms. Users may send their friends videos, emojis, and messages with direct messaging. TikTok has also included a feature to create a video based on the user's comments. Influencers often use the "live" feature. This feature is only available for those who have at least 1,000 followers and are over 16 years old. If over 18, the user's followers can send virtual "gifts" that can be later exchanged for money. The app's "react" feature allows users to film their reaction to a specific video, over which it is placed in a small window that is movable around the screen. Its "duet" feature allows users to film a video aside from another video.
Pd complexes of CPhos catalyze the synthesis of 3-cyclopentylindole derivatives, dihydrobenzofurans, and trans-bicyclic sulfamides. It has also been used to synthesize palladacycle precatalysts for Negishi coupling of secondary alkylzinc reagents with aryl halides.
The city was procuring only electric buses as of 2021, gradually replacing the diesel bus fleet. Moscow was expected to become the leading European city in its share of electric versus gas fuel in public transit by 2019.
In adults, the primary metabolic pathway for paracetamol is glucuronidation. This yields a relatively non-toxic metabolite, which is excreted into bile and passed out of the body. A small amount of the drug is metabolized via the cytochrome P-450 pathway (to be specific, CYP3A4 and CYP2E1) into NAPQI, which is extremely toxic to liver tissue, as well as being a strong biochemical oxidizer. In an average adult, only a small amount (approximately 10% of a therapeutic paracetamol dose) of NAPQI is produced, which is inactivated by conjugation with glutathione (GSH). The amount of NAPQI produced differs in certain populations. The minimum dosage at which paracetamol causes toxicity usually is 7.5 to 10g in the average person. The lethal dose is usually between 10 g and 15 g. Concurrent alcohol intake lowers these thresholds significantly. Chronic alcoholics may be more susceptible to adverse effects due to reduced glutathione levels. Other populations may experience effects at lower or higher dosages depending on differences in P-450 enzyme activity and other factors which affect the amount of NAPQI produced. In general, however, the primary concern is accidental or intentional paracetamol overdose. When a toxic dose of paracetamol is ingested, the normal glucuronide pathway is saturated and large amounts of NAPQI are produced. Liver reserves of glutathione are depleted by conjugation with this excess NAPQI.
Sources: en.wikipedia.org
==== MeSH E05.393.525 – molecular probe techniques ==== MeSH E05.393.525.085 – biotinylation MeSH E05.393.525.100 – blotting, northern MeSH E05.393.525.150 – blotting, southern MeSH E05.393.525.225 – blotting, southwestern MeSH E05.393.525.300 – branched dna signal amplification assay MeSH E05.393.525.640 – oligonucleotide array sequence analysis MeSH E05.393.525.680 – protein array analysis MeSH E05.393.525.700 – random amplified polymorphic dna technique MeSH E05.393.525.870 – two-hybrid system techniques
=== Space science and planetary research === Space science and planetary research at the University of Arizona are largely conducted through the Lunar and Planetary Laboratory (LPL), which has led or contributed to numerous NASA missions. The university received more than $325 million for the LPL to lead NASA's 2007–08 Phoenix Mars Mission, which explored the Martian Arctic. It later received another $800 million for the OSIRIS-REx mission, the first mission in U.S. history to collect a sample from an asteroid. The LPL's contributions to the Cassini mission orbiting Saturn were larger than those of any other university in the world. University researchers designed and operated the spacecraft's atmospheric radiation and imaging investigations. The university also operates the HiRISE camera aboard the Mars Reconnaissance Orbiter. The spacecraft reached Mars in March 2006 after traveling 300 million miles. The University of Arizona-designed camera was led by planetary scientist Alfred McEwen, the project's principal investigator. HiRISE captured high-resolution images of the planet. In 2011, University of Arizona alumnus and planetary scientist Lujendra Ojha and his research team used HiRISE imagery to identify evidence of liquid water on the surface of Mars. NASA confirmed the discovery in 2015. The university receives more NASA grants annually than the next nine top NASA-Jet Propulsion Laboratory-funded universities combined. In August 2007, the University of Arizona, under the direction of planetary scientist Peter Smith, led the Phoenix Mars Mission.
=== Pharmacodynamics === Myristicin interferes with multiple signaling pathways and enzyme processes in the body. It is known to be a weak inhibitor of monoamine oxidase (MAO), an enzyme in humans that metabolizes neurotransmitters (for example, serotonin, dopamine, epinephrine, and norepinephrine). It lacks the basic nitrogen atom that is typical of monoamine oxidase inhibitors (MAOIs), potentially explaining a weaker inhibitory effect. While smaller concentrations of MAOIs may not cause problems, there are additional warnings regarding drug interactions. Those taking antidepressants that are MAOIs (such as phenelzine, isocarboxazid, tranylcypromine or selegiline) or taking selective serotonin reuptake inhibiting (SSRI) antidepressants should avoid essential oils rich in myristicin, such as that of nutmeg and anise. Myristicin does not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. In laboratory studies, myristicin is cytotoxic. Specifically, it stimulates cytochrome c release, which activates caspase cascades and induces early apoptosis in the cells. Myristicin has also been shown to inhibit cytochrome P450 enzymes, which are responsible for metabolizing a variety of substrates including hormones and toxins, allowing these substrates to accumulate. The pharmacology of myristicin and other nutmeg constituents has been reviewed.
SrSO4 + 2 C → SrS + 2 CO2 About 300,000 tons are processed in this way annually. The metal is produced commercially by reducing strontium oxide with aluminium. The strontium is distilled from the mixture. Strontium metal can also be prepared on a small scale by electrolysis of a solution of strontium chloride in molten potassium chloride:
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
RP-HPLC is widely used for purity and impurity profiling. Mass spectrometry confirms identity.